Walgreens Cuts Earnings Guidance After a Challenging Second Quarter -- Update
02 Avril 2019 - 3:04PM
Dow Jones News
By Aisha Al-Muslim
Walgreens Boots Alliance Inc. cut its earnings expectations for
the fiscal year after the drugstore chain said it faced its most
difficult quarter since the merger of Alliance Boots and
Walgreens.
In the most recent quarter, the Deerfield, Ill.-based company
said its profit fell to $1.16 billion, or $1.24 a share, from $1.35
billion, or $1.36 a share, a year earlier. Adjusted earnings came
in at $1.64 a share, lower than the $1.72 a share that analysts
polled by Refinitiv expected.
"The market challenges and macro trends we have been discussing
for some time accelerated," Walgreens Chief Executive Stefano
Pessina said Tuesday. "During the quarter, we saw significant
reimbursement pressure, compounded by lower generic deflation, as
well as continued consumer market challenges in the U.S. and
U.K.."
Walgreens shares fell about 8% to $58.40 in premarket trading.
Shares are up about 0.6% over the past year.
For fiscal 2019, Walgreens now expects adjusted earnings per
share at constant currency rates to be roughly flat, lower than its
previous guidance for 7% to 12% growth.
For the second quarter, Walgreens said sales rose 4.6% to $34.53
billion as the company continues integrating Rite Aid stores.
Analysts, according to Refinitiv, expected Walgreens to report
sales of $34.56 billion.
In the quarter, U.S. retail pharmacy sales rose 7.3% to $26.3
billion, due in large part to higher prescription volumes from the
acquisition of Rite Aid stores.
Same-store pharmacy sales increased 1.9%, while comparable
retail sales were down 3.8%. Comparable retail sales were down
primarily due to a weak cough, cold and flu season, the company
said. Also playing a role in the decline were a drop in seasonable
merchandise sales and a shift away from sales of products like
tobacco.
"We are going to be more aggressive in our response to these
rapidly shifting trends," Mr. Pessina said.
The company has been testing tobacco-free stores in the U.S. due
to pressure from federal regulators, activists and some
investors.
In early March, Walgreens shares fell for several days after the
Food and Drug Administration in February called the company out for
being a top violator among pharmacies illegally selling tobacco
products to minors.
In response, Walgreens said it has a zero-tolerance policy on
selling tobacco to minors and any employee found to be in violation
is subject to termination.
In December, Walgreens said it was taking steps over three years
to eliminate more than $1 billion in annual costs through a new
plan.
After the disappointing quarter, Walgreens increased its annual
cost-savings target to more than $1.5 billion by fiscal 2022.
The company expects to improve its performance in fiscal 2020,
resulting in mid-to-high single-digit growth in adjusted earnings
per share in the following years, it said.
The company's initiatives will result in significant
restructuring and other special charges as they are implemented,
the company said. The company recognized pretax charges of $179
million for the six months ended Feb. 28, related primarily to the
pharmaceutical wholesale and retail pharmacy international
divisions.
The drugstore chain has been shrinking its retail footprint as
it searches for other avenues of growth to ward off competition
from CVS Health Corp. and Amazon.com Inc.
Walgreens has struck about a dozen partnership deals in the past
couple of years in a bid to increase revenue by increasing pharmacy
orders and getting customers to make other in-store purchases.
Write to Aisha Al-Muslim at aisha.al-muslim@wsj.com
(END) Dow Jones Newswires
April 02, 2019 08:49 ET (12:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Walgreens Boots Alliance (NASDAQ:WBA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Walgreens Boots Alliance (NASDAQ:WBA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024